← Research ProtocolsLL-37
STUDIED EXPOSURE MAP / 2014
LL-37
tested in research.
The actual doses, concentrations or exposure levels reported by the source — kept attached to route, population, timeframe and evidence type.
HUMAN / FIRST-IN-MAN DOSE RESPONSEWOUND REPAIR AND REGENERATIONSTUDIED EXPOSURE ≠ RECOMMENDED DOSE
STUDIED EXPOSURE / SOURCE DATANumbers below describe this research source only.
0.5 mg/mL
topical · twice weekly
1.6 mg/mL
topical · twice weekly
3.2 mg/mL
topical · twice weekly
Context: These values are topical solution concentrations applied to wounds, not injectable doses. Route is part of the evidence and must stay attached to the number.
NOT A DOSING GUIDEENHANCED is reporting what researchers administered or tested. It does not convert these numbers into a personal dose, reconstitution plan, cycle, titration schedule or recommendation.
SOURCE / WOUND REPAIR AND REGENERATION
Treatment with LL-37 in hard-to-heal venous leg ulcers: randomized placebo-controlled clinical trial
Study design and tested exposure are separated from recommendation. Route and population stay visible so the numbers cannot be read without context.
2014
01 / DESIGNRandomized, placebo-controlled first-in-man wound study
02 / POPULATION / MODEL34 participants with hard-to-heal venous leg ulcers
03 / ROUTETopical wound application
04 / TIMEFRAME3-week treatment period with follow-up
05 / PRIMARY QUESTIONSafety and dose-response wound-healing measures
It supports a factual statement about the exposure tested in this research source. It does not establish that the same exposure is appropriate, effective or safe outside that source.
Cathelicidin and innate-immunity research
Study exposure ≠ personal protocol. Animal doses are never converted to human-equivalent amounts here. IV, topical, oral, intranasal and subcutaneous exposures are not treated as interchangeable.